Westfield reports 0 shares in Bicycle Therapeutics (NASDAQ: BCYC)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Bicycle Therapeutics plc filed Amendment No. 2 to a Schedule 13G reporting that Westfield Capital Management Company, L.P. beneficially owned 0 shares of Common Stock as of 12/31/2025. The amendment is signed by Brandi McMahon and dated 03/03/2026.
Positive
- None.
Negative
- None.
FAQ
What does Bicycle Therapeutics' Schedule 13G/A filing say about Westfield Capital's holdings (BCYC)?
The filing states that Westfield Capital Management Company, L.P. beneficially owned 0 shares of Bicycle Therapeutics common stock as of 12/31/2025. The amendment is signed and dated 03/03/2026.
When is the ownership date reported by Westfield Capital in the BCYC amendment?
The reported ownership date is 12/31/2025. The Schedule 13G/A amendment indicates beneficial ownership measured as of that date and the signature on the amendment is dated 03/03/2026.
Who signed the Schedule 13G/A amendment for Westfield Capital in the BCYC filing?
The amendment is signed by Brandi McMahon, identified as Vice President, Deputy Chief Compliance Officer. The signature block shows the form was dated 03/03/2026.
Does the Schedule 13G/A amendment indicate any voting or dispositive power for Westfield Capital (BCYC)?
The filing shows 0 for sole and shared voting power and 0 for sole and shared dispositive power as of 12/31/2025, consistent with the reported beneficial ownership of 0 shares.
What class of securities is covered in the Westfield Capital 13G/A for Bicycle Therapeutics (BCYC)?
The filing covers Common Stock of Bicycle Therapeutics plc and lists the CUSIP 088786108 alongside the ownership and voting power disclosures dated 12/31/2025.